Evotec SE
XETRA:EVT
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Evotec SE
Note Receivable
Evotec SE
Note Receivable Peer Comparison
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/xetra/gxi.png)
Competitive Note Receivable Analysis
Latest Figures & CAGR of Competitors
Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
E
|
Evotec SE
XETRA:EVT
|
Note Receivable
€102.2m
|
CAGR 3-Years
36%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
![]() |
Gerresheimer AG
XETRA:GXI
|
Note Receivable
€9.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
S
|
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
|
Note Receivable
€411k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Evotec SE's Note Receivable?
Note Receivable
102.2m
EUR
Based on the financial report for Mar 31, 2024, Evotec SE's Note Receivable amounts to 102.2m EUR.
What is Evotec SE's Note Receivable growth rate?
Note Receivable CAGR 5Y
41%
Over the last year, the Note Receivable growth was 45%. The average annual Note Receivable growth rates for Evotec SE have been 36% over the past three years , 41% over the past five years .